BMO Capital raised the firm’s price target on Protagonist Therapeutics (PTGX) to $72 from $62 and keeps an Outperform rating on the shares. The firm is adjusting its model to reflect the strength of the company’s new plaque psoriasis and ulcerative colitis data, the analyst tells investors in a research note. BMO also cites the additional upside on 2025 updates for these programs as well as rusfertide, Protagonist’s hepcidin mimetic for polycythemia vera.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics price target raised to $80 from $54 at H.C. Wainwright
- Protagonist reports top line results from Phase 2b study of icotrokinra
- Promising Potential of Protagonist Therapeutics’ Icotrokinra in Psoriasis Treatment: A New Benchmark for Oral Therapies
- 3 Best Stocks to Buy Now, 3/10/2025, According to Top Analysts
- Protagonist Therapeutics: Buy Rating Backed by Promising Phase 3 Results and Market Potential of Icotrokinra
Questions or Comments about the article? Write to editor@tipranks.com